Bernie Sanders (I-VT)

Prescription Drug Price Relief Act of 2025

S. 1818 · Senate bill Health

A bill from an independent · See all 7 cosponsors

Last activity — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

The Prescription Drug Price Relief Act of 2025 aims to significantly lower prescription drug prices for patients in the United States. It establishes a process for the Secretary of Health and Human Services to identify brand name drugs with excessive prices. A drug may be deemed excessively priced if its domestic average manufacturing price exceeds the median price in five reference countries: Canada, the United Kingdom, Germany, France, and Japan. For drugs not meeting that specific criteria, the Secretary can determine if a price is excessive based on various other factors like patient population and drug value. Once a drug is identified as excessively priced, the Secretary can waive government-granted exclusivities and grant open, non-exclusive licenses to allow others to produce or import the drug. This mechanism is intended to end government-granted monopolies for manufacturers charging high prices.

Yes· 3 of 9

  • Scored +10

    Does this lower the price of prescription medicines?

    The bill's central purpose is to significantly lower the costs of prescription drugs by ending brand-name monopolies.

  • Scored +8

    Would people over 65 be better off under this?

    Lower drug prices provide significant financial relief to seniors who often rely on prescription medications.

  • Scored +8

    Would households on low incomes be better off under this?

    Reducing drug prices directly improves the purchasing power of low-income households.

The opposite

  • Scored -6

    Does this make patent and copyright rules fairer?

    The bill reduces traditional intellectual property protections by waiving exclusivities for certain drugs.

  • Scored -5

    Would business owners be better off under this?

    Pharmaceutical manufacturers and business owners face new regulatory burdens and potential loss of monopoly profits.